Gelonghui, Feb. 27 | The A-share diet pill concept changed in the afternoon. Zhongsheng Pharmaceutical went up and down, while Nuotai Biotech, Borui Pharmaceuticals, Changshan Pharmaceutical, Shengnuo Biotech, Kanghui Pharmaceuticals, and Uningwei followed suit. According to the news, according to the drug clinical trial registration and information disclosure platform of the State Drug Administration, on February 21, the multinational pharmaceutical company Amjin announced a phase 1 study on the diet drug AMG 133. Unlike semeglutide and tirpotide, which are weekly formulations, AMG 133 is administered every 4 weeks, that is, once a month, subcutaneously, which means better adherence for patients.
A股异动丨减肥药概念股拉升，众生药业涨停
A-share changes丨Diet drug concept stocks rose, and Zhongsheng Pharmaceutical rose and stopped
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.